Showing 2261-2270 of 2657 results for "".
- Alcon to Acquire Ivantis, Maker of the Hydrus Microstent for Surgical Glaucomahttps://modernod.com/news/alcon-to-acquire-ivantis-and-its-hydrus-microstent-for-surgical-glaucoma-strengthening-global-ophthalmology-portfolio/2480410/Alcon announced its intention to acquire Ivantis, developer and manufacturer of the Hydrus Microstent. The deal will strenghten Alcon's surgical glaucoma portfolio and allow it to enter the growing MIGS category. Under terms of the deal, Alcon will pay $475 million in upfr
- Alcon Inaugurates Company’s Largest European Eye Health Education and Training Center in Barcelonahttps://modernod.com/news/alcon-inaugurates-companys-largest-european-eye-health-education-and-training-centre-in-barcelona/2480404/Alcon officially opened the new Alcon Experience Center (AEC) in Barcelona, one of Europe's largest eye health education and training facilities, offering eye care professionals the opportunity to learn and gain hands-on experience with the latest innovations in ophthalmology and optometry. T
- Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopiahttps://modernod.com/news/eyenovia-announces-first-patient-enrolled-in-phase-3-vision-2-trial-of-microline-for-presbyopia/2480400/Eyenovia announced that the first patient has been enrolled in the company’s second Phase 3 clinical trial of MicroLine, its proprietary pilocarpine formulation for temporary improvement in presbyopia, known as VISION-2. “Following the co
- Heru Releases re:Vive 2.0: A Single Wearable Platform with 6 Vision Diagnostic Modalities that Support 5 CPT Codeshttps://modernod.com/news/heru-releases-revive-20-a-single-wearable-platform-with-6-vision-diagnostic-modalities-that-support-5-cpt-codes/2480396/Heru announced it is expanding the capabilities of re:Vive by Heru, the company’s wearable gamified diagnostic solution, to include three new testing modalities: Color Vision CPT 92283, Contrast Sensitivity, and Dark Adaptation CPT 92284. “Since the inception of Heru, our go
- Visus Therapeutics Appoints David Guyer, MD, as Chairman of the Board, and Names Ted Danse as Head of Business Developmenthttps://modernod.com/news/visus-therapeutics-appoints-david-guyer-md-as-chairman-of-the-board-and-names-ted-danse-as-head-of-business-development/2480395/Visus Therapeutics announced the appointment of ophthalmology and industry expert David Guyer, MD, as the chairman of the Board after serving as an advisor since the company’s inception, and life sciences veteran Ted Danse as the head of business development. “I&rs
- CooperVision Presents Presbyopia Research, Introduces MyDay Daily Disposable Multifocal at Academy 2021https://modernod.com/news/coopervision-presents-presbyopia-research-introduces-myday-daily-disposable-multifocal-at-academy-2021/2480390/As part of the American Academy of Optometry 2021 virtual press conference, CooperVision presented results of research into the daily complexity of dealing with presbyopia and how this may affect clinical choices. The work was conducted in support of the launch of CooperVision’s new MyDay&n
- FDA Clears Emergency Use of Comirnaty in Children Aged 5 to 11https://modernod.com/news/fda-clears-emergency-use-of-comirnaty-in-children-aged-5-to-11/2480386/The FDA on Friday authorized emergency use of Pfizer and BioNTech's Comirnaty for the prevention of COVID-19 to include children 5 through 11 years of age. The vaccine is administered as a two-dose primary series, 21 days apart, but at a lower 10-mcg dose than that used for individuals 12 yea
- Collaboration Agreement Aims to Develop Orally Administered Treatment for Diabetic Macular Edema and Wet AMDhttps://modernod.com/news/collaboration-agreement-aims-to-develop-orally-administered-treatment-for-diabetic-macular-edema-and-wet-amd/2480380/Korea-based biopharmaceutical company Curacle announced that it has entered into an exclusive license and collaboration agreement with Théa Open Innovation (TOI) for the development and commercialization of Curacle's CU06-RE, which is being examined as an orall
- Eyenovia Announces Reclassification of MydCombi as Drug-Device Combination Product by FDAhttps://modernod.com/news/eyenovia-announces-reclassification-of-mydcombi-as-drug-device-combination-product-by-fda/2480375/In a Complete Response Letter (CRL) from the FDA, Eyenovia announced that MydCombi, the company’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, has been reclassified as a drug-device com
- Ocular Therapeutix's Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Does Not Meet Primary Endpointhttps://modernod.com/news/ocular-therapeutixs-phase-2-clinical-trial-of-otx-csi-for-the-treatment-of-dry-eye-disease-does-not-meet-primary-endpoint/2480372/Topline results from Ocular Therapeutix's phase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED) did not meet its primary endpoint of increased tear production at 12 weeks. The phase 2, US-based, randomized, double-masked,